CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,380,336 | +166.2% | 42,400 | +92.7% | 0.26% | +107.0% |
| Q4 2022 | $894,300 | -37.8% | 22,000 | 0.0% | 0.13% | -34.4% |
| Q3 2022 | $1,438,000 | +7.6% | 22,000 | 0.0% | 0.20% | -6.7% |
| Q2 2022 | $1,337,000 | -3.2% | 22,000 | 0.0% | 0.21% | +17.4% |
| Q1 2022 | $1,381,000 | -17.2% | 22,000 | 0.0% | 0.18% | +6.6% |
| Q4 2021 | $1,667,000 | -83.9% | 22,000 | -76.1% | 0.17% | -89.6% |
| Q3 2021 | $10,322,000 | -38.2% | 92,214 | -10.6% | 1.61% | -37.4% |
| Q2 2021 | $16,693,000 | +907.4% | 103,114 | +852.6% | 2.57% | +1072.1% |
| Q4 2020 | $1,657,000 | +94.3% | 10,825 | +6.1% | 0.22% | -51.5% |
| Q3 2020 | $853,000 | -32.5% | 10,200 | -40.7% | 0.45% | -37.3% |
| Q2 2020 | $1,264,000 | +81.6% | 17,200 | +4.9% | 0.72% | -11.0% |
| Q1 2020 | $696,000 | -48.7% | 16,400 | -26.5% | 0.81% | -38.2% |
| Q4 2019 | $1,358,000 | – | 22,300 | – | 1.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |